Active, not recruitingPhase 3NCT04488822

A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT

Studying Tenosynovial giant cell tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Daiichi Sankyo Co., Ltd.
Principal Investigator
Global Clinical Leader
Daiichi Sankyo
Intervention
Pexidartinib(drug)
Enrollment
40 target
Eligibility
18 years · All sexes
Timeline
20202026

Study locations (9)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04488822 on ClinicalTrials.gov

Other trials for Tenosynovial giant cell tumor

Additional recruiting or active studies for the same condition.

See all trials for Tenosynovial giant cell tumor

← Back to all trials